Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Aug 20;100(16):1144-54.
doi: 10.1093/jnci/djn255. Epub 2008 Aug 11.

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

Collaborators, Affiliations
Randomized Controlled Trial

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

Anna Bill-Axelson et al. J Natl Cancer Inst. .

Abstract

Background: The benefit of radical prostatectomy in patients with early prostate cancer has been assessed in only one randomized trial. In 2005, we reported that radical prostatectomy improved prostate cancer survival compared with watchful waiting after a median of 8.2 years of follow-up. We now report results after 3 more years of follow-up.

Methods: From October 1, 1989, through February 28, 1999, 695 men with clinically localized prostate cancer were randomly assigned to radical prostatectomy (n = 347) or watchful waiting (n = 348). Follow-up was complete through December 31, 2006, with histopathologic review and blinded evaluation of causes of death. Relative risks (RRs) were estimated using the Cox proportional hazards model. Statistical tests were two-sided.

Results: During a median of 10.8 years of follow-up (range = 3 weeks to 17.2 years), 137 men in the surgery group and 156 in the watchful waiting group died (P = .09). For 47 of the 347 men (13.5%) who were randomly assigned to surgery and 68 of the 348 men (19.5%) who were not, death was due to prostate cancer. The difference in cumulative incidence of death due to prostate cancer remained stable after about 10 years of follow-up. At 12 years, 12.5% of the surgery group and 17.9% of the watchful waiting group had died of prostate cancer (difference = 5.4%, 95% confidence interval [CI] = 0.2 to 11.1%), for a relative risk of 0.65 (95% CI = 0.45 to 0.94; P = .03). The difference in cumulative incidence of distant metastases did not increase beyond 10 years of follow-up. At 12 years, 19.3% of men in the surgery group and 26% of men in the watchful waiting group had been diagnosed with distant metastases (difference = 6.7%, 95% CI = 0.2 to 13.2%), for a relative risk of 0.65 (95% CI = 0.47 to 0.88; P = .006). Among men who underwent radical prostatectomy, those with extracapsular tumor growth had 14 times the risk of prostate cancer death as those without it (RR = 14.2, 95% CI = 3.3 to 61.8; P < .001).

Conclusion: Radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial flow diagram of the 695 men randomly assigned in the Scandinavian Prostate Cancer Group-4 study. RT = radiation therapy; RP = radical prostatectomy.
Figure 2
Figure 2
Cumulative incidence with 95% confidence intervals (CIs) at 4, 8, and 12 years of endpoints for all patients. A) Overall mortality: relative risk (RR) = 0.82, 95% CI = 0.65 to 1.03; P = .09. B) Prostate cancer (PC) death: RR = 0.65, 95% CI = 0.45 to 0.94; P = .03. C) Metastases: RR = 0.65, 95% CI = 0.47 to 0.88; P = .006. D) Local progression: RR = 0.36, 95% CI = 0.27 to 0.47; P < .001. E) Hormonal treatment: RR = 0.54, 95% CI = 0.44 to 0.68; P < .001. F) Other palliative treatment: RR = 0.63, 95% CI = 0.41 to 0.97; P = .04. P values (two-sided) were calculated using Gray's test.
Figure 3
Figure 3
Cumulative incidence of endpoints by age group. A) Overall mortality: Age < 65: Relative risk (RR) 0.59, 95% confidence interval (CI) = 0.41 to 0.85; P = .004. Age ≥ 65: RR = 1.04, 95% CI = 0.77 to 1.4; P = .81. B) Prostate cancer (PC) death. Age < 65: RR = 0.5, 95% CI = 0.3 to 0.84; P = .01. Age ≥ 65: RR = 0.87, 95% CI = 0.51 to 1.49; P = .55. C) Metastases. Age < 65: RR = 0.52, 95% CI = 0.34 to 0.81; P = .006. Age ≥ 65: RR = 0.8, 95% CI = 0.51 to 1.27; P = .28. P values (two-sided) were calculated using Gray's test.
Figure 4
Figure 4
Cumulative incidence of prostate cancer mortality among men who were randomly assigned to radical prostatectomy and underwent radical prostatectomy within 1 year after randomization. A) Mortality by extracapsular tumor growth. Relative risk (RR) = 0.05, 95% confidence interval (CI) = 0.01 to 0.22; P < .001. B) Mortality by Gleason score of radical prostatectomy specimens. Gleason score 7 vs Gleason score 8–10, RR = 0.24, 95% CI = 0.11 to 0.49; P < .001. Gleason score 2–6, RR was not estimated (no events). P values (two-sided) were calculated using Gray's test.

Comment in

Similar articles

Cited by

References

    1. Kvåle R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99(24):1881–1887. - PubMed
    1. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet. 1994;343(8903):958–960. - PubMed
    1. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–878. - PubMed
    1. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–1984. - PubMed
    1. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781–799. - PubMed

Publication types

Substances